Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018.
Future Oncol
; 19(6): 451-461, 2023 Feb.
Article
en En
| MEDLINE
| ID: mdl-37039001
ABSTRACT
Aim:
Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma.Methods:
This was a retrospective cohort study linking routine healthcare data with systemic anticancer therapy prescriptions for patients starting immunotherapy or targeted treatments between 1 November 2010 and 31 December 2017 in the west of Scotland.Results:
Among 362 patients identified, median overall survival varied between 18.5 months (95% CI 14.4-not estimable) for ipilimumab/nivolumab combination and 5.6 months (95% CI 4.5-7.3) for dabrafenib, but there were differences in the characteristics of each regimen cohort. Raised lactate dehydrogenase levels and Eastern Cooperative Oncology Group performance status ≥2 negatively impacted overall survival.Conclusion:
The patients had a shorter median overall survival than those in pivotal trials. This was expected, given that this real-world cohort included patients with poorer prognostic indicators, typically excluded from trials.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Primarias Secundarias
/
Melanoma
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Reino Unido